Building ‘Smart’ Cell-Based Therapies
A Northwestern synthetic biology team has created a new technology for modifying human cells to create programmable therapeutics that could travel the body and selectively target cancer and other sites of disease.
Engineering cell-based, biological devices that monitor and modify human physiology is a promising frontier in clinical synthetic biology. However, no existing technology enabled bioengineers to build such devices that sense a patient’s physiological state and respond in a customized fashion.
“The project addressed a key gap in the synthetic biology toolbox,” says Joshua Leonard, assistant professor of chemical and biological engineering in Northwestern’s McCormick School of Engineering and Applied Science. “There was no way to engineer cells in a manner that allowed them to sense key pieces of information about their environment, which could indicate whether the engineered cell is in healthy tissue or sitting next to a tumor.”
Funded by the National Academies Keck Futures Initiative and the Defense Advanced Research Projects Agency, the research is available to read online in the journal ACS Synthetic Biology.
Leonard’s team worked for nearly four years to close this gap. The end result is a protein biosensor that sits on the surface of a cell and can be programmed to sense specific external factors. For example, the engineered cell could detect big, soluble protein molecules that indicate that it’s next to a tumor. When the biosensor detects such a factor, it sends a signal into the engineered cell’s nucleus to activate a gene expression program, such as the production of tumor-killing proteins or chemicals. Since this toxic program would be activated only near tumor cells, such an approach could minimize side effects as well as improve therapeutic benefits.
Called a Modular Extracellular Sensor Architecture (MESA), the biosensor platform is completely self-contained so that several different biosensors can be present in a single cell without interfering with one another, allowing bioengineers to build increasingly sophisticated functional programs. The platform is also highly modular, enabling the biosensors to be customized to recognize factors of relevance to various patients’ needs.
“By linking the output of these biosensors to genetic programs, one can build in a certain logical command, such as ‘turn the output gene on when you sense this factor but not that factor,’” Leonard explains. “In that way, you could program a cell-based therapy to specify which cells it should kill.”
Leonard says doctors could potentially collect immune cells from a patient’s body, engineer the cells using MESA, and put them back into the patient. From there, the cells would do the work of detecting cancer or the disease they are designed to identify.
The Latest on: Smart Cell-Based Therapies
[google_news title=”” keyword=”Smart Cell-Based Therapies” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Smart Cell-Based Therapies
- Cell-based Therapies for Parkinson's Diseaseon November 30, 2023 at 4:00 pm
Nevertheless, owing to the relatively circumscribed nature of the nigrostriatal lesion in PD, dopaminergic cell transplantation has emerged as a potentially reparative therapy for the disease.
- SMART researchers pave the way for faster and safer T-cell therapy through novel contamination-detection methodon November 27, 2023 at 7:37 am
SMART CAMP’s breakthrough method ... In a paper titled “Machine learning-based detection of adventitious microbes in T-cell therapy cultures using long-read sequencing”, published recently ...
- Stem cell-based therapies for stroke in newbornson November 23, 2023 at 7:14 am
No evidence is currently available to evaluate the benefits and harms of stem cell-based interventions for treatment of stroke in newborn infants. We identified no ongoing studies. Future clinical ...
- Cell & gene therapy: the leading companies in CAR-T cell-based therapies revealedon November 14, 2023 at 4:00 pm
CAR-T cell-based therapies is a key innovation area in cell & gene therapy CAR-T cell-based therapies, short for chimeric antigen receptor T-cell therapies, represent a groundbreaking approach to ...
- Pluripotent Stem Cell–Based Therapy for Heart Diseaseon July 12, 2023 at 10:37 pm
After a myocardial infarction (heart attack), irreversible loss of contracting heart muscle cells occurs ... Current therapies designed to treat heart attack patients in the acute setting include ...
- Cell Therapieson June 28, 2023 at 5:00 pm
The conventional approach of cell-based assay workflow was time- and resource-consuming. Now, the cryoprotectant technology CryoShield™ from CryoLogyx together with the controlled and scalable plate ...
- The Emerging Key to Smart Cell Therapy Manufacturingon September 25, 2021 at 1:16 am
In 1998, Isabelle Rivière was recruited to lead a new cell and gene therapy facility at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York. MSKCC was pioneering cell therapy for blood ...
- T cell-based therapies for canceron August 24, 2020 at 10:16 am
A major focus for the group is developing T-cell based therapies for cancer and in this regard we are engineering T cells to make them more effective at recognising the tumour. We also have an ...
- Cell-Based Therapies for Diabetic Microvascular Complicationson June 24, 2020 at 12:16 pm
In recent years accumulating evidence suggest that diabetic patients may greatly benefit from cell-based therapies involving adult stem or progenitor cells. Cell therapies from a variety of sources ...
via Bing News